AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14557430 — intervention group
Group type: COMPARATOR
Intervention: Oral daily ibandronate (2.5 mg)
Number of subjects: 235
Study 14557430 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (weekly and daily ibandronate)
Number of subjects: 235
Study 10698393 — intervention group
Group type: EXPERIMENTAL
Intervention: A balanced mixed amino acid infusion (200 mL/hr) for 30 minutes immediately after the operation
Number of subjects: 22
Study 10698393 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study 9088782 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous nicotine injections (2 x 0.3 mg)
Number of subjects: 36
Study 9088782 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous nicotine injections (2 x 0.6 mg)
Number of subjects: 36
Study 9088782 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 36
Study 9088782 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous nicotine (both doses)
Number of subjects: 36
Study 9088782 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous nicotine (0.6 mg)
Number of subjects: 36
Study 1490435 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam, intramuscularly at a level of 50 to 80 mg/kg body weight per dose every 8 h for 7 days
Number of subjects: 57
Study 1490435 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol, orally in a dose of 50 to 70 mg/kg body weight every 6 h for 12 days
Number of subjects: 57
Study 2987636 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4‐9 analog (40 mg)
Number of subjects: 0
Study 2987636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29943838 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifungal agents (systemic and topical)
Number of subjects: 208
Study 28831618 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral HIV prevention intervention integrating in-person and mobile phone delivered HIV risk reduction counseling, and daily, personalized text or voice messages.
Number of subjects: 100
Study 28831618 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) comparison condition
Number of subjects: 100
Study 26296407 — intervention group
Group type: EXPERIMENTAL
Intervention: Good performance preceded by poor performance
Number of subjects: 61
Study 26296407 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline performance preceded by good performance
Number of subjects: 61
Study 26296407 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative comments
Number of subjects: 61
Study 24565345 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative group (IG) - guardian received an information leaflet about anesthesia
Number of subjects: 72
Study 24565345 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - guardian received conventional information about anesthesia
Number of subjects: 72
Study 21946964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction (MBSR)
Number of subjects: 29
Study 21946964 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 29
Study 18838938 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic epinephrine
Number of subjects: 22
Study 18838938 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol
Number of subjects: 22
Study 18838938 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic albuterol
Number of subjects: 22
Study 18838938 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 22
Study 18838938 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (including saline)
Number of subjects: 22
Study 18838938 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilator treatments
Number of subjects: 22
Study 16122897 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (BBN training program)
Number of subjects: 34
Study 16122897 — intervention group
Group type: COMPARATOR
Intervention: Balint group (control)
Number of subjects: 34
Study 12618286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 2.5 mg
Number of subjects: 2
Study 12618286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 2.5 mg + Naloxone 0.4 mg
Number of subjects: 2
Study 12618286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 5 mg
Number of subjects: 2
Study 12618286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 5 mg + Naloxone 0.4 mg
Number of subjects: 2
Study 10556449 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm gas
Number of subjects: 100
Study 10556449 — intervention group
Group type: COMPARATOR
Intervention: Cold gas
Number of subjects: 100
Study 8712112 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Transluminal Coronary Angioplasty (PTCA)
Number of subjects: 395
Study 1929022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice aimed at selectively increasing potassium intake (group 1)
Number of subjects: 54
Study 1929022 — intervention group
Group type: COMPARATOR
Intervention: Customary diet unchanged (group 2)
Number of subjects: 54
Study 6762195 — intervention group
Group type: EXPERIMENTAL
Intervention: chemo‐immunotherapy (BCG plus intradermal leukaemic blast cells)
Number of subjects: 264
Study 6762195 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy alone
Number of subjects: 264
Study 31901284 — intervention group
Group type: EXPERIMENTAL
Intervention: Expander with differential opening (EDO)
Number of subjects: 46
Study 31901284 — intervention group
Group type: COMPARATOR
Intervention: Hyrax expander
Number of subjects: 46
Study 31901284 — intervention group
Group type: COMPARATOR
Intervention: Both EDO and Hyrax expander
Number of subjects: 46
Study 31159814 — intervention group
Group type: COMPARATOR
Intervention: 8-miRNA signature
Number of subjects: 120
Study 31159814 — intervention group
Group type: COMPARATOR
Intervention: 16-miRNA signature
Number of subjects: 120
Study 30003569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooling strategy using mixed blood samples from randomly selected subjects
Number of subjects: 0
Study 30003569 — intervention group
Group type: COMPARATOR
Intervention: Simple random sampling method
Number of subjects: 0
Study 27224744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling (COOL)
Number of subjects: 21
Study 27224744 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming (WARM)
Number of subjects: 21
Study 27224744 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral (NEUT)
Number of subjects: 21
Study 24397441 — intervention group
Group type: EXPERIMENTAL
Intervention: Double balloon catheter (mechanical method group, 67 cases)
Number of subjects: 126
Study 24397441 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone 10mg controlled‐release vaginal insert (pharmacological method group, 59 cases)
Number of subjects: 126
Study 24397441 — intervention group
Group type: EXPERIMENTAL
Intervention: Double balloon catheter
Number of subjects: 126
Study 24397441 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone vaginal insert
Number of subjects: 126
Study 22715371 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients
Number of subjects: 19
Study 22715371 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 19
Study 20237044 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 24
Study 20237044 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electrical stimulation
Number of subjects: 24
Study 20237044 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency electrical stimulation
Number of subjects: 24
Study 20237044 — intervention group
Group type: EXPERIMENTAL
Intervention: All forms of acupuncture
Number of subjects: 24
Study 17338763 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant anterior LA ablation during PVAI
Number of subjects: 200
Study 17338763 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant ablation)
Number of subjects: 200
Study 17338763 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant anterior LA ablation during PVAI (for persistent/permanent AF)
Number of subjects: 200
Study 17338763 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant ablation, for persistent/permanent AF)
Number of subjects: 200
Study 17338763 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant anterior LA ablation during PVAI (for paroxysmal AF)
Number of subjects: 200
Study 17338763 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant ablation, for paroxysmal AF)
Number of subjects: 200
Study 15834273 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (median dose: 410 mg/day)
Number of subjects: 1010
Study 15834273 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee (median intake: 725 ml/day)
Number of subjects: 1010
Study 12031981 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment for 10 days
Number of subjects: 0
Study 12031981 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of insulin treatment
Number of subjects: 0
Study 12031981 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic control subjects
Number of subjects: 0
Study 10051048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (initial dose 0.03 to 0.4 mg/kg, median 0.052 mg/kg; maintenance dose 0.03 to 0.13 mg/kg/day)
Number of subjects: 14
Study 7721409 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg on each of 5 days preceding the study)
Number of subjects: 6
Study 7721409 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatrilat (200 mg IV)
Number of subjects: 6
Study 7721409 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enalapril and candoxatrilat
Number of subjects: 6
Study 7721409 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5 mg)
Number of subjects: 6
Study 1959863 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg ursodeoxycholic acid alone (group A)
Number of subjects: 282
Study 1959863 — intervention group
Group type: COMPARATOR
Intervention: Combination of 500 mg ursodeoxycholic acid and 500 mg chenodeoxycholic acid (group B)
Number of subjects: 282
Study 6786952 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (30 IU added to each 1006 kcal of nutrient solution)
Number of subjects: 16
Study 6786952 — intervention group
Group type: COMPARATOR
Intervention: Control group (nutrient solution of hypertonic glucose and amino acids, 44.7 +/- 9.0 kcal/kg/day)
Number of subjects: 16
Study 31833718 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-alpha reductase inhibitors (5-ARIs) for at least 12 months
Number of subjects: 423
Study 31833718 — intervention group
Group type: COMPARATOR
Intervention: Untreated with 5-alpha reductase inhibitors (5-ARIs)
Number of subjects: 423
Study 28040526 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ)
Number of subjects: 87
Study 28040526 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 87
Study 25928772 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cell phone support intervention
Number of subjects: 37
Study 24266968 — intervention group
Group type: EXPERIMENTAL
Intervention: rATG + rituximab
Number of subjects: 0
Study 24266968 — intervention group
Group type: EXPERIMENTAL
Intervention: rATG + bortezomib
Number of subjects: 0
Study 24266968 — intervention group
Group type: EXPERIMENTAL
Intervention: rATG + rituximab + bortezomib
Number of subjects: 0
Study 24266968 — intervention group
Group type: COMPARATOR
Intervention: rATG
Number of subjects: 0
Study 21555748 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based training intervention for general practitioners over a 2-year period
Number of subjects: 255
Study 21555748 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 255
Study 21555748 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated by specialists (internal comparison group)
Number of subjects: 255
Study 18762438 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release oral oxycodone co-administered with naloxone (10 mg/day, 20 mg/day, 40 mg/day)
Number of subjects: 202
Study 18762438 — intervention group
Group type: COMPARATOR
Intervention: Prolonged-release oral naloxone (20 mg/day and 40 mg/day)
Number of subjects: 202
Study 18762438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 17525906 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour infusion of daunorubicin (DNR) at a dose of 36 mg/m²
Number of subjects: 178
Study 17525906 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour infusion of daunorubicin (DNR) at a dose of 36 mg/m²
Number of subjects: 178
Study 17525906 — intervention group
Group type: COMPARATOR
Intervention: 1-hour infusion of daunorubicin (DNR)
Number of subjects: 178
Study 17525906 — intervention group
Group type: COMPARATOR
Intervention: 24-hour infusion of daunorubicin (DNR)
Number of subjects: 178
Study 12698257 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscocanalostomy
Number of subjects: 25
Study 12698257 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C
Number of subjects: 25
Study 11071831 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 874
Study 11071831 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous physical activity
Number of subjects: 874
Study 11071831 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 65+
Number of subjects: 874
Study 11071831 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance self-efficacy score
Number of subjects: 874
Study 11071831 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 874
Study 11071831 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic fitness
Number of subjects: 874
Study 11071831 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity levels
Number of subjects: 874
Study 8929199 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilted stripes (15 degrees)
Number of subjects: 45
Study 8929199 — intervention group
Group type: COMPARATOR
Intervention: Vertical stripes
Number of subjects: 45
Study 1408301 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (5%)
Number of subjects: 31
Study 1408301 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (0.9%)
Number of subjects: 31
Study 1408301 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental pain
Number of subjects: 31
Study 1408301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain from memory
Number of subjects: 31
Study 1408301 — intervention group
Group type: COMPARATOR
Intervention: Baseline recordings
Number of subjects: 31
Study 2866607 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine 200 mg three times a day
Number of subjects: 181
Study 2866607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 10872406 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemomechanical caries removal system (CRS)
Number of subjects: 47
Study 10872406 — intervention group
Group type: COMPARATOR
Intervention: Conventional caries removal (control)
Number of subjects: 47
Study 10872406 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CRS and control procedures
Number of subjects: 47
Study 31175436 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Self‐Determination Gynecological Cancer (GSD‐GYN‐C)
Number of subjects: 0
Study 31175436 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 30225985 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) injections (100 or 30 units)
Number of subjects: 50
Study 30225985 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 50
Study 28271453 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-specific inhibition training
Number of subjects: 22
Study 28271453 — intervention group
Group type: COMPARATOR
Intervention: Control condition (free exploration of food pictures)
Number of subjects: 22
Study 26298674 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal preventative intervention including a student social relationship/emotional health curriculum and parent/caregiver parenting education
Number of subjects: 2027
Study 26298674 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 2027
Study 23457222 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravitational shunt valves
Number of subjects: 145
Study 23457222 — intervention group
Group type: COMPARATOR
Intervention: Programmable valves (Control)
Number of subjects: 145
Study 21091365 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang
Number of subjects: 2704
Study 21091365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2704
Study 18596714 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits by trained community health workers (CHWs) within 3 days of birth
Number of subjects: 3495
Study 18596714 — intervention group
Group type: COMPARATOR
Intervention: No home visit by CHWs
Number of subjects: 3495
Study 16990384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow-derived progenitor cells (BMC)
Number of subjects: 204
Study 16990384 — intervention group
Group type: COMPARATOR
Intervention: Placebo medium
Number of subjects: 204
Study 15107600 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (LS) 0.5 mg four times daily
Number of subjects: 24
Study 15107600 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (LS) 0.5 mg four times daily with felodipine (FD) 5 mg once daily
Number of subjects: 24
Study 15107600 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 24
Study 15107600 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (FD) 5 mg once daily
Number of subjects: 24
Study 11048468 — intervention group
Group type: COMPARATOR
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 48
Study 11048468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 48
Study 8838439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride (150 mg twice daily)
Number of subjects: 24
Study 8838439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8838439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.15 g kg-1)
Number of subjects: 24
Study 8838439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.3 g kg-1)
Number of subjects: 24
Study 8838439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.6 g kg-1)
Number of subjects: 24
Study 1595589 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic magnesium administration (CMA) 4.5 g/d for 4 weeks
Number of subjects: 12
Study 1595589 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 12
Study 6375411 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile block with 0.5 percent bupivacaine
Number of subjects: 0
Study 6375411 — intervention group
Group type: COMPARATOR
Intervention: No nerve block
Number of subjects: 0
Study 31477748 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free diquafosol administered 6 times daily after surgery
Number of subjects: 0
Study 31477748 — intervention group
Group type: COMPARATOR
Intervention: Preservative-containing diquafosol administered 6 times daily after surgery
Number of subjects: 0
Study 31477748 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free hyaluronate administered 6 times daily after surgery
Number of subjects: 0
Study 31477748 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free diquafosol
Number of subjects: 0
Study 29504880 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Codeine (Tylex 30 mg: acetaminophen 500 mg/codeine 30 mg)
Number of subjects: 105
Study 29504880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 29504880 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Codeine (Tylex)
Number of subjects: 105
Study 26420678 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-based phosphate binder + Nicotinamide (100 mg twice or three times daily)
Number of subjects: 60
Study 26420678 — intervention group
Group type: COMPARATOR
Intervention: Calcium-based phosphate binder
Number of subjects: 60
Study 25089860 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-mg triamcinolone acetonide subacromial corticosteroid injection (CSI)
Number of subjects: 104
Study 25089860 — intervention group
Group type: COMPARATOR
Intervention: 6 sessions of manual physical therapy
Number of subjects: 104
Study 22471392 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 75 mg for 4 weeks
Number of subjects: 18
Study 22471392 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg for 4 weeks
Number of subjects: 18
Study 22471392 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg for 4 weeks
Number of subjects: 18
Study 20733968 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithmic approach to management of lumbar spinal stenosis
Number of subjects: 1
Study 17931342 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (0.75 mg)
Number of subjects: 115
Study 17931342 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 115
Study 15667242 — intervention group
Group type: EXPERIMENTAL
Intervention: Benchmarking
Number of subjects: 0
Study 15667242 — intervention group
Group type: EXPERIMENTAL
Intervention: Benchmarking dataset
Number of subjects: 0
Study 11929327 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (aldosterone antagonist) added to existing therapy
Number of subjects: 0
Study 11289497 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute myocardial infarction (AMI)
Number of subjects: 76
Study 11289497 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable angina pectoris (AP)
Number of subjects: 76
Study 11289497 — intervention group
Group type: EXPERIMENTAL
Intervention: Old myocardial infarction (OMI)
Number of subjects: 76
Study 11289497 — intervention group
Group type: COMPARATOR
Intervention: Control group (atypical chest pain)
Number of subjects: 76
Study 9011455 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (250 microg bolus injection)
Number of subjects: 20
Study 9011455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20